Thomas J. Kester Acquires 30,991 Shares of InspireMD, Inc. (NYSE:NSPR) Stock

Key Points

• Thomas J. Kester, a director at InspireMD, Inc., acquired **30,991 shares** at an average price of **$2.42**, increasing his total holdings to **420,758 shares** valued at over **$1 million**.
• InspireMD's stock traded at **$2.69**, with its **1-year price range** between **$1.99 and $3.80**, reflecting a market capitalization of **$82.41 million**.
• Recent institutional activity includes **Huntleigh Advisors** increasing its position by **5.8%** and **several firms** acquiring new positions valued around **$27,000**, indicating growing interest from institutional investors.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Thomas J. Kester purchased 30,991 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The stock was bought at an average price of $2.42 per share, with a total value of $74,998.22. Following the completion of the purchase, the director owned 420,758 shares of the company's stock, valued at $1,018,234.36. This trade represents a 7.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

InspireMD Price Performance

NYSE:NSPR traded down $0.07 during trading hours on Tuesday, hitting $2.60. The stock had a trading volume of 48,585 shares, compared to its average volume of 103,497. The company has a 50 day simple moving average of $2.43 and a two-hundred day simple moving average of $2.61. InspireMD, Inc. has a one year low of $1.99 and a one year high of $3.80. The firm has a market capitalization of $79.65 million, a price-to-earnings ratio of -3.47 and a beta of 0.60.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NSPR. Wall Street Zen assumed coverage on shares of InspireMD in a report on Monday, May 5th. They set a "sell" rating for the company. Piper Sandler lowered their target price on shares of InspireMD from $4.50 to $4.00 and set an "overweight" rating on the stock in a report on Monday, May 12th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NSPR. Uniting Wealth Partners LLC purchased a new stake in shares of InspireMD during the 1st quarter valued at $27,000. Brown Advisory Inc. purchased a new position in InspireMD in the 1st quarter worth $27,000. Renaissance Technologies LLC purchased a new position in InspireMD in the 4th quarter worth $27,000. XTX Topco Ltd purchased a new position in InspireMD in the 1st quarter worth $38,000. Finally, Vestia Personal Wealth Advisors purchased a new position in InspireMD in the 2nd quarter worth $41,000. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.